Physician profile
Steven O Speiser
NPI 1598709990
$7,928.05
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,077 · 2021: $2,864 · 2022: $1,967 · 2023: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,650.69 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,585.08 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,071.65 | 2019-2023 | Rexulti, Abilify Maintena |
| Abbvie INC. | $851.79 | 2021-2023 | Vraylar |
| Indivior INC. | $557.29 | 2019-2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $426.55 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $400.91 | 2019-2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $366.77 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $343.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.41 | 2020-2022 | |
| Noven Therapeutics, LLC | $216.41 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $112.39 | 2019 | |
| Bioxcel Therapeutics, INC. | $22.40 | 2023 | Igalmi |
| Allergan, INC. | $19.32 | 2020 | |
| Uswm, LLC | $17.27 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $14.85 | 2021 | |
| Gilead Sciences, INC. | $12.47 | 2019 | |
| Eisai INC. | $11.18 | 2020 | |
| Neuronetics, INC. | $6.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Speiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.